- Records
- 19
- Recruiting
- 11
- Recruiting sites
- 613
- Countries
- 18
ClinicalTrials.gov registry snapshot / 2026-07-24Peptide trials,
Peptide trials,
without the maze.
Search every official registry record matched to 13 tracked peptide and next-generation weight-loss programs. Find current status, phase, enrollment, countries, US states, recruiting cities, postal areas, completion timing, and the direct NCT source.
268unique NCT records
13named programs
53countries represented
1,840recruiting cities
11registry result modules
Recruiting footprint by program
Study status is not drug rank.
Bar length shows registry-listed sites individually marked Recruiting. Larger programs can create larger counts. This does not compare efficacy, safety, approval odds, sponsor quality, or enrollment availability.
- Records
- 52
- Recruiting
- 10
- Recruiting sites
- 170
- Countries
- 7
- Records
- 37
- Recruiting
- 10
- Recruiting sites
- 73
- Countries
- 3
- Records
- 24
- Recruiting
- 10
- Recruiting sites
- 935
- Countries
- 28
- Records
- 27
- Recruiting
- 6
- Recruiting sites
- 1,581
- Countries
- 36
- Records
- 30
- Recruiting
- 5
- Recruiting sites
- 155
- Countries
- 6
- Records
- 8
- Recruiting
- 4
- Recruiting sites
- 339
- Countries
- 23
- Records
- 31
- Recruiting
- 3
- Recruiting sites
- 774
- Countries
- 34
- Records
- 15
- Recruiting
- 3
- Recruiting sites
- 3
- Countries
- 1
- Records
- 34
- Recruiting
- 2
- Recruiting sites
- 450
- Countries
- 27
- Records
- 9
- Recruiting
- 2
- Recruiting sites
- 4
- Countries
- 3
- Records
- 9
- Recruiting
- 1
- Recruiting sites
- 8
- Countries
- 1
- Records
- 5
- Recruiting
- 0
- Recruiting sites
- 0
- Countries
- 0
Official registry finder
Filter the exact records.
Search names, former codes, NCT IDs, sponsors, interventions, conditions, cities, and postal codes. Filtered URLs are shareable but intentionally excluded from search indexing so this page remains the canonical source.
72matching registry records
Matching recruiting site observations289
| Program and record | Status | Phase and enrollment | Locations | Primary completion | Registry update | Source |
|---|---|---|---|---|---|---|
| A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and ObesityNCT07567001 / HF-POLARIS / Novo Nordisk A/S | RecruitingVerified 2026-07 | Phase 35,610 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jul 23, 2029estimated | Jul 15, 2026ClinicalTrials.gov | Open NCT07567001 ↗ |
| AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep ApnoeaNCT07571005 / AMAZE 3 / Novo Nordisk A/S | RecruitingVerified 2026-07 | Phase 3300 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jul 12, 2028estimated | Jul 13, 2026ClinicalTrials.gov | Open NCT07571005 ↗ |
| AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep ApnoeaNCT07571109 / AMAZE 4 / Novo Nordisk A/S | RecruitingVerified 2026-07 | Phase 3300 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jun 26, 2028estimated | Jul 13, 2026ClinicalTrials.gov | Open NCT07571109 ↗ |
| A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body WeightNCT07253285 / Novo Nordisk A/S | RecruitingVerified 2026-07 | Phase 3460 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Mar 20, 2030estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07253285 ↗ |
| A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or ObesityNCT07243171 / Hangzhou Sciwind Biosciences Co., Ltd. | RecruitingVerified 2025-10 | Phase 1 / Phase 284 estimated | 1 matching recruitingBeijing, Beijing Municipality, 100029, China | Aug 3, 2026estimated | Jan 28, 2026ClinicalTrials.gov | Open NCT07243171 ↗ |
| A Study of XW003 in Obese Participants With Obstructive Sleep Apnea But Not Receive Positive Airway Pressure TherapyNCT07387094 / Hangzhou Sciwind Biosciences Co., Ltd. | RecruitingVerified 2026-01 | Phase 3140 estimated | 1 matching recruitingBeijing, Beijing Municipality, China | Dec 16, 2027estimated | Apr 14, 2026ClinicalTrials.gov | Open NCT07387094 ↗ |
| A Study of XW003 in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure TherapyNCT07434050 / Hangzhou Sciwind Biosciences Co., Ltd. | RecruitingVerified 2026-01 | Phase 3140 estimated | 1 matching recruitingShanghai, Shanghai Municipality, 200025, China | Jun 19, 2028estimated | Apr 13, 2026ClinicalTrials.gov | Open NCT07434050 ↗ |
| A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 DiabetesNCT07282600 / ENLIGHTEN-2 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 31,035 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jan 2028estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07282600 ↗ |
| A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 DiabetesNCT07321886 / ENLIGHTEN-1 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 31,980 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Mar 2028estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07321886 ↗ |
| Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or OverweightNCT07353931 / ENLIGHTEN-4 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 3900 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Mar 2028estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07353931 ↗ |
| A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or OverweightNCT07369011 / ENLIGHTEN-3 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 3800 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Mar 2028estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07369011 ↗ |
| A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly IncretinNCT07392190 / ENLIGHTEN-6 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 3900 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jun 2028estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07392190 ↗ |
| A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 DiabetesNCT07351045 / Enith1 / Hoffmann-La Roche | RecruitingVerified 2026-07 | Phase 32,000 estimated | 14 matching recruitingZhenjiang, Jiangsu, 212002, China / Xianyang, Shaanxi, 712000, China / Jinan, Shandong, 250013, China / 11 more areas | Jul 24, 2028estimated | Jul 20, 2026ClinicalTrials.gov | Open NCT07351045 ↗ |
| A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 DiabetesNCT07351058 / Enith2 / Hoffmann-La Roche | RecruitingVerified 2026-07 | Phase 31,600 estimated | 20 matching recruitingKaifeng, Henan, 475001, China / Xuzhou, Jiangsu, 221002, China / Zhenjiang, Jiangsu, 212002, China / 17 more areas | Aug 7, 2028estimated | Jul 20, 2026ClinicalTrials.gov | Open NCT07351058 ↗ |
| A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Enicepatide in Generally Healthy Adult Chinese ParticipantsNCT07626515 / Hoffmann-La Roche | RecruitingVerified 2026-07 | Phase 136 estimated | 1 matching recruitingBeijing, 100034, China | Apr 30, 2027estimated | Jul 9, 2026ClinicalTrials.gov | Open NCT07626515 ↗ |
| A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 DiabetesNCT07670416 / Hoffmann-La Roche | RecruitingVerified 2026-07 | Phase 3300 estimated | 12 matching recruitingXianyang, Shaanxi, 712000, China / Ningbo, Zhejiang, 315010, China / Beijing, 100044, China / 9 more areas | Feb 24, 2028estimated | Jul 14, 2026ClinicalTrials.gov | Open NCT07670416 ↗ |
| Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityNCT07037433 / MARITIME-CV / Amgen | RecruitingVerified 2026-07 | Phase 312,800 estimated | 40 matching recruitingBengbu, Anhui, 233300, China / Beijing, Beijing Municipality, 100020, China / Beijing, Beijing Municipality, 100050, China / 37 more areas | Jun 30, 2028estimated | Jul 24, 2026ClinicalTrials.gov | Open NCT07037433 ↗ |
| Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityNCT07037459 / MARITIME-HF / Amgen | RecruitingVerified 2026-06 | Phase 35,056 estimated | 50 matching recruitingHefei, Anhui, 230601, China / Beijing, Beijing Municipality, 100020, China / Beijing, Beijing Municipality, 100037, China / 46 more areas | Jun 30, 2028estimated | Jul 2, 2026ClinicalTrials.gov | Open NCT07037459 ↗ |
| Efficacy of Mazdutide for Treating PCOSNCT06519656 / Shanghai Zhongshan Hospital | RecruitingVerified 2024-10 | Phase 1 / Phase 250 estimated | 1 matching recruitingShanghai, 200032, China | Dec 31, 2025estimated | Oct 24, 2024ClinicalTrials.gov | Open NCT06519656 ↗ |
| A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With ObesityNCT06862908 / Innovent Biologics (Suzhou) Co. Ltd. | RecruitingVerified 2025-07 | Phase 2141 estimated | 1 matching recruitingBeijing, Beijing Municipality, 100037, China | Sep 24, 2026estimated | Jul 11, 2025ClinicalTrials.gov | Open NCT06862908 ↗ |
| A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2NCT06931028 / Innovent Biologics (Suzhou) Co. Ltd. | RecruitingVerified 2025-06 | Phase 3260 estimated | 1 matching recruitingBeijing, 100191, China | May 7, 2027estimated | Jun 29, 2025ClinicalTrials.gov | Open NCT06931028 ↗ |
| A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)NCT06937749 / Innovent Biologics (Suzhou) Co. Ltd. | RecruitingVerified 2025-11 | Phase 2165 estimated | 1 matching recruitingBeijing, Beijing Municipality, 100044, China | Apr 30, 2026estimated | Nov 20, 2025ClinicalTrials.gov | Open NCT06937749 ↗ |
| GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)NCT07083154 / The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | RecruitingVerified 2026-03 | Phase 3420 estimated | 6 matching recruitingChangzhou, Jiangsu, China / Nanjing, Jiangsu, 210000, China / Nanjing, Jiangsu, 210008, China / 3 more areas | Aug 1, 2029estimated | Mar 5, 2026ClinicalTrials.gov | Open NCT07083154 ↗ |
| A Study of IBI362 in Chinese Adolescents With Obesity or OverweightNCT07255209 / Innovent Biologics (Suzhou) Co. Ltd. | RecruitingVerified 2026-01 | Phase 3180 estimated | 1 matching recruitingHangzhou, Zhejiang, 310052, China | Oct 31, 2027estimated | Jan 8, 2026ClinicalTrials.gov | Open NCT07255209 ↗ |
| Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/ObesityNCT07469800 / Innovent Biologics (Suzhou) Co. Ltd. | RecruitingVerified 2026-05 | Phase 3336 estimated | 1 matching recruitingShanghai, Shanghai Municipality, China | Aug 1, 2026estimated | May 27, 2026ClinicalTrials.gov | Open NCT07469800 ↗ |
| ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight ManagementNCT07517042 / Shanghai Zhongshan Hospital | RecruitingVerified 2025-12 | Not applicable420 estimated | 13 matching recruitingChongqing, Chongqing Municipality, 400000, China / Fuzhou, Fujian, 350000, China / Xiamen, Fujian, 361003, China / 8 more areas | Dec 2028estimated | Apr 8, 2026ClinicalTrials.gov | Open NCT07517042 ↗ |
| GLP-1 Therapy After Bariatric Surgery in Chinese Patients With ObesityNCT07633639 / China-Japan Friendship Hospital | RecruitingVerified 2026-05 | Not applicable200 estimated | 1 matching recruitingBeijing, China | May 1, 2028estimated | Jun 8, 2026ClinicalTrials.gov | Open NCT07633639 ↗ |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)NCT07165028 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 34,500 estimated | 39 matching recruitingBeijing, 100015, China / Beijing, 100034, China / Beijing, 100050, China / 36 more areas | Aug 2030estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07165028 ↗ |
| Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are OverweightNCT07467447 / GZBF / Hudson Biotech | RecruitingVerified 2026-03 | Phase 2300 estimated | 1 matching recruitingShenzhen, Guangdong, 518036, China | Mar 14, 2027estimated | Mar 12, 2026ClinicalTrials.gov | Open NCT07467447 ↗ |
| LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver FibrosisNCT06632444 / Boehringer Ingelheim | RecruitingVerified 2026-07 | Phase 31,800 estimated | 49 matching recruitingBeijing, 100015, China / Beijing, 100044, China / Beijing, 100050, China / 44 more areas | Dec 27, 2031estimated | Jul 9, 2026ClinicalTrials.gov | Open NCT06632444 ↗ |
| LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have CirrhosisNCT06632457 / Boehringer Ingelheim | RecruitingVerified 2026-07 | Phase 31,590 estimated | 34 matching recruitingBeijing, 100015, China / Beijing, 100044, China / Beijing, 100050, China / 30 more areas | Jun 5, 2029estimated | Jul 9, 2026ClinicalTrials.gov | Open NCT06632457 ↗ |
| Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe ObesityNCT07135141 / SMART / Beijing Friendship Hospital | Not yet recruitingVerified 2025-08 | Not applicable256 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Sep 30, 2027estimated | Aug 21, 2025ClinicalTrials.gov | Open NCT07135141 ↗ |
| A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) InhibitorNCT07417306 / Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Not yet recruitingVerified 2026-02 | Phase 3912 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Aug 30, 2027estimated | Feb 18, 2026ClinicalTrials.gov | Open NCT07417306 ↗ |
| Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE)NCT07654062 / DREAM-PRE / Shandong Provincial Hospital | Not yet recruitingVerified 2026-06 | Phase 4150 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jun 2028estimated | Jun 17, 2026ClinicalTrials.gov | Open NCT07654062 ↗ |
| Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or ObesityNCT07657676 / China National Center for Cardiovascular Diseases | Not yet recruitingVerified 2026-06 | Phase 4116 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Oct 31, 2027estimated | Jun 18, 2026ClinicalTrials.gov | Open NCT07657676 ↗ |
| Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)NCT07718126 / PRIME / West China Hospital | Not yet recruitingVerified 2026-07 | Phase 2 / Phase 360 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Aug 31, 2028estimated | Jul 21, 2026ClinicalTrials.gov | Open NCT07718126 ↗ |
| A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)NCT07073417 / Hangzhou Sciwind Biosciences Co., Ltd. | Active, not recruitingVerified 2025-07 | Phase 2163 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Feb 27, 2027estimated | Apr 13, 2026ClinicalTrials.gov | Open NCT07073417 ↗ |
| A Study of IBI362 9 mg in Chinese Adults With ObesityNCT06164873 / Innovent Biologics (Suzhou) Co. Ltd. | Active, not recruitingVerified 2024-08 | Phase 3462 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jun 27, 2025estimated | Aug 27, 2024ClinicalTrials.gov | Open NCT06164873 ↗ |
| A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）NCT06884293 / Innovent Biologics (Suzhou) Co. Ltd. | Active, not recruitingVerified 2026-05 | Phase 3479 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Dec 31, 2026estimated | May 12, 2026ClinicalTrials.gov | Open NCT06884293 ↗ |
| Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe ObesityNCT07000955 / Innovent Biologics (Suzhou) Co. Ltd. | Active, not recruitingVerified 2025-12 | Phase 1 / Phase 298 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Sep 30, 2026estimated | Dec 15, 2025ClinicalTrials.gov | Open NCT07000955 ↗ |
| A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants After 10 Days of Oral DosingNCT06820476 / Novo Nordisk A/S | CompletedVerified 2025-08 | Phase 129 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | May 14, 2025actual | Aug 20, 2025ClinicalTrials.gov | Open NCT06820476 ↗ |
| A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants When Injected Under the Skin.NCT07121153 / Novo Nordisk A/S | CompletedVerified 2026-02 | Phase 136 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Dec 20, 2025actual | Feb 17, 2026ClinicalTrials.gov | Open NCT07121153 ↗ |
| A Research Study of How NNC0174-0833 Behaves in Chinese Volunteers Who Are Normal Weight, Overweight or With ObesityNCT05254158 / Novo Nordisk A/S | CompletedVerified 2023-11 | Phase 124 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Sep 7, 2022actual | Nov 7, 2023ClinicalTrials.gov | Open NCT05254158 ↗ |
| A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose WeightNCT05996848 / REDEFINE 6 / Novo Nordisk A/S | CompletedVerified 2026-01 | Phase 3300 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jan 6, 2025actual | Jan 9, 2026ClinicalTrials.gov | Open NCT05996848 ↗ |
| A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorNCT06065540 / REIMAGINE 2 / Novo Nordisk A/S | CompletedVerified 2026-07 | Phase 32,734 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Nov 19, 2025actual | Jul 8, 2026ClinicalTrials.gov | Open NCT06065540 ↗ |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without MetforminNCT06323161 / REIMAGINE 3 / Novo Nordisk A/S | CompletedVerified 2025-11 | Phase 3274 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Sep 9, 2025actual | Nov 28, 2025ClinicalTrials.gov | Open NCT06323161 ↗ |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and ExerciseNCT06323174 / REIMAGINE 1 / Novo Nordisk A/S | CompletedVerified 2026-03 | Phase 3189 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Oct 1, 2025actual | Apr 2, 2026ClinicalTrials.gov | Open NCT06323174 ↗ |
| A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DMNCT05680129 / Hangzhou Sciwind Biosciences Co., Ltd. | CompletedVerified 2023-07 | Phase 3623 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jul 3, 2024actual | May 8, 2025ClinicalTrials.gov | Open NCT05680129 ↗ |
| A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM PatientsNCT05680155 / Hangzhou Sciwind Biosciences Co., Ltd. | CompletedVerified 2023-07 | Phase 3211 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jun 12, 2024actual | Sep 10, 2025ClinicalTrials.gov | Open NCT05680155 ↗ |
| A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or ObesityNCT05813795 / Hangzhou Sciwind Biosciences Co., Ltd. | CompletedVerified 2024-07 | Phase 3664 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jun 20, 2024actual | Apr 30, 2025ClinicalTrials.gov | Open NCT05813795 ↗ |
| A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or DigoxinNCT06335134 / Hangzhou Sciwind Biosciences Co., Ltd. | CompletedVerified 2023-07 | Phase 157 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jan 8, 2024actual | May 8, 2025ClinicalTrials.gov | Open NCT06335134 ↗ |
| A Study of XW003 Injection in Chinese Adolescents With ObesityNCT07143227 / Hangzhou Sciwind Biosciences Co., Ltd. | CompletedVerified 2025-08 | Phase 148 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Apr 18, 2026actual | May 20, 2026ClinicalTrials.gov | Open NCT07143227 ↗ |
| Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity SubjectsNCT04440345 / Innovent Biologics (Suzhou) Co. Ltd. | CompletedVerified 2023-11 | Phase 1 / Phase 260 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jun 16, 2021actual | Nov 28, 2023ClinicalTrials.gov | Open NCT04440345 ↗ |
| Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DMNCT04466904 / Innovent Biologics (Suzhou) Co. Ltd. | CompletedVerified 2021-07 | Phase 1 / Phase 242 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | May 28, 2021actual | Jul 23, 2021ClinicalTrials.gov | Open NCT04466904 ↗ |
| Clinical Study of IBI362 in Healthy Chinese Male SubjectsNCT04773977 / Innovent Biologics (Suzhou) Co. Ltd. | CompletedVerified 2021-03 | Phase 124 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Mar 9, 2021actual | Jul 8, 2021ClinicalTrials.gov | Open NCT04773977 ↗ |
| A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese SubjectsNCT04904913 / Innovent Biologics (Suzhou) Co. Ltd. | CompletedVerified 2025-11 | Phase 2328 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Mar 29, 2023actual | Nov 17, 2025ClinicalTrials.gov | Open NCT04904913 ↗ |
| A Study of IBI362 in Chinese Patients With Type 2 DiabetesNCT04965506 / Innovent Biologics (Suzhou) Co. Ltd. | CompletedVerified 2023-12 | Phase 2252 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Apr 28, 2022actual | Dec 27, 2023ClinicalTrials.gov | Open NCT04965506 ↗ |
| A Study of IBI362 in Participants With Type 2 DiabetesNCT05606913 / Innovent Biologics (Suzhou) Co. Ltd. | CompletedVerified 2024-08 | Phase 3731 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jan 26, 2024actual | Aug 23, 2024ClinicalTrials.gov | Open NCT05606913 ↗ |
| A Study of IBI362 in Participants With Obesity or OverweightNCT05607680 / Innovent Biologics (Suzhou) Co. Ltd. | CompletedVerified 2024-11 | Phase 3610 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Aug 21, 2023actual | Nov 12, 2024ClinicalTrials.gov | Open NCT05607680 ↗ |
| A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and ExerciseNCT05628311 / Innovent Biologics (Suzhou) Co. Ltd. | CompletedVerified 2024-08 | Phase 3319 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Oct 25, 2023actual | Aug 20, 2024ClinicalTrials.gov | Open NCT05628311 ↗ |
| Pharmacokinetics of IBI362 in Subjects With and Without Renal ImpairmentNCT05793450 / Innovent Biologics (Suzhou) Co. Ltd. | CompletedVerified 2024-02 | Phase 120 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Sep 18, 2023actual | Feb 20, 2024ClinicalTrials.gov | Open NCT05793450 ↗ |
| A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese SubjectsNCT05815680 / Innovent Biologics (Suzhou) Co. Ltd. | CompletedVerified 2023-11 | Phase 148 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Aug 18, 2023actual | Nov 14, 2023ClinicalTrials.gov | Open NCT05815680 ↗ |
| A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and ObesityNCT06184568 / Innovent Biologics (Suzhou) Co. Ltd. | CompletedVerified 2026-06 | Phase 3349 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Sep 17, 2025actual | Jun 11, 2026ClinicalTrials.gov | Open NCT06184568 ↗ |
| This is a Study to Evaluate the Pharmacokinetics and Safety of IBI362 in Chinese Adolescents With ObesityNCT06536023 / Innovent Biologics (Suzhou) Co. Ltd. | CompletedVerified 2025-09 | Phase 136 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jul 22, 2025actual | Sep 12, 2025ClinicalTrials.gov | Open NCT06536023 ↗ |
| A Study of LY3437943 in Chinese Participants With Obesity Or OverweightNCT05548231 / Eli Lilly and Company | CompletedVerified 2023-08 | Phase 132 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jul 27, 2023actual | Aug 14, 2023ClinicalTrials.gov | Open NCT05548231 ↗ |
| A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose WeightNCT04667377 / Boehringer Ingelheim | CompletedVerified 2023-10Registry results posted | Phase 2387 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Sep 15, 2022actual | Nov 2, 2023ClinicalTrials.gov | Open NCT04667377 ↗ |
| A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)NCT04771273 / Boehringer Ingelheim | CompletedVerified 2024-11Registry results posted | Phase 2295 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Nov 9, 2023actual | Dec 3, 2024ClinicalTrials.gov | Open NCT04771273 ↗ |
| A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose WeightNCT06066515 / SYNCHRONIZE™-1 / Boehringer Ingelheim | CompletedVerified 2026-03 | Phase 3726 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Dec 2, 2025actual | Mar 12, 2026ClinicalTrials.gov | Open NCT06066515 ↗ |
| A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose WeightNCT06066528 / SYNCHRONIZE™-2 / Boehringer Ingelheim | CompletedVerified 2026-06 | Phase 3755 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Dec 12, 2025actual | Jun 24, 2026ClinicalTrials.gov | Open NCT06066528 ↗ |
| A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)NCT06077864 / Boehringer Ingelheim | CompletedVerified 2026-07 | Phase 35,531 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jun 1, 2026actual | Jul 23, 2026ClinicalTrials.gov | Open NCT06077864 ↗ |
| A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose WeightNCT06214741 / Boehringer Ingelheim | CompletedVerified 2026-04 | Phase 3307 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jul 29, 2025actual | Apr 30, 2026ClinicalTrials.gov | Open NCT06214741 ↗ |
| A Study in Chinese People With Overweight or Obesity to Test How Different Doses of Survodutide Are Taken up in the BodyNCT06492135 / Boehringer Ingelheim | CompletedVerified 2025-04 | Phase 130 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Apr 15, 2025actual | Apr 23, 2025ClinicalTrials.gov | Open NCT06492135 ↗ |
Recruiting location footprint
Country and US state routes.
Counts are site observations across registry records, not unique facilities. The same research center can appear in multiple studies. Open the exact NCT record before treating a location as current.
Clinical trial finder FAQ
Status, location, and enrollment are different fields.
These answers prevent the most common registry-search errors before a reader follows an official source.
Are any Retatrutide clinical trials recruiting?
Yes. This 2026-07-24 snapshot contains 2 Retatrutide registry records with an overall Recruiting status and 450 listed sites individually marked Recruiting. Overall status does not mean every site is open, and neither status establishes eligibility or enrollment. Open the exact NCT record and verify the individual location before contacting a study team.
How do I find a peptide clinical trial near me?
Enter a city or postal code, optionally add a country or US state, and then open the exact ClinicalTrials.gov record. This finder retains location rows individually marked Recruiting but omits facility and personal contact fields. Confirm current recruitment, eligibility, official contact route, and travel requirements on the registry. Peptide Local does not enroll participants.
Does Recruiting mean I can join the trial?
No. Recruiting is a registry status, not an eligibility decision or appointment. A study can be recruiting overall while some listed locations are not yet recruiting, active but closed, completed, suspended, or missing a current site status. The study team applies the protocol's eligibility and consent process.
Are the drugs in this clinical trial finder FDA approved?
A ClinicalTrials.gov record is not FDA approval. The finder covers investigational programs and can also include studies involving components or comparators with separate regulatory histories. Approval must be verified on the exact FDA label or regulator record, not inferred from a phase, sponsor, trial result, or recruiting status.
Why do only some registry records show posted results?
11 of 268 records in this snapshot expose a ClinicalTrials.gov results module. A record without posted registry results can still have a publication or sponsor announcement elsewhere, while a posted module still requires careful interpretation. Results availability is not a quality rank.
How current is the peptide clinical trial data?
The registry data timestamp is July 24, 2026 at 9:00 AM UTC. The refresh workflow searches exact intervention names and aliases, deduplicates by NCT ID, preserves multi-program studies, and stores overall and individual-site status separately. Registry fields can change after that timestamp, so the direct source remains authoritative for enrollment decisions.
Evidence boundary
A registry finder, not an enrollment service.
A dated transformation of ClinicalTrials.gov intervention-search records for thirteen named Peptide Local pipeline programs. Study sponsors or investigators submit and maintain registry records. Overall status, individual-site status, enrollment, locations, completion dates, and results availability can change. Recruiting status does not establish eligibility, enrollment, treatment access, regulatory approval, routine availability, or a favorable benefit-risk conclusion.
Peptide Local omits personal contact details and does not screen participants, recommend a protocol, interpret eligibility, arrange treatment, or authenticate commercial products that reuse an investigational program's name.
Read the official API documentation ↗Understand evidence categories →